Sagimet Biosciences Inc. Series A Common Stock
$11.09
Market Cap
$689.34M
Shares Outstanding
62.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 14, 2023
Round Lot
100
Locale
US
Day Open
$11.16
Day High
$11.40
Day Low
$10.80
Volume
1.85M
VWAP
$11.11
Prev Close
$11.17
Transactions
--
Acc. Volume
--
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) closed the 2026-09-18 session at $11.09, down 0.72% versus the previous close (-0.08). The stock opened at $11.16 and traded between $10.80 and $11.40 during that session. Session trading volume was 1.9M shares. The volume-weighted average price (VWAP) is $11.11.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Sagimet Biosciences Inc. Series A Common Stock has a market capitalization of $689.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. SGMT is listed on the XNAS exchange. The company employs approximately 16 people. Sagimet Biosciences Inc. Series A Common Stock is headquartered in FOSTER CITY, CA. The recorded listing date is 2023-07-14.
On this page you can find market SGMT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.